Researchers have reported three major discoveries: water molecules actively driving gene transcription, a large-scale map of 90,000 human gene interactions, and a single-molecule enzyme screening ...
The ethics of using safe gene therapies to improve the health and cognition of Down syndrome children and adults.
CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.
The U.S. FDA has begun piloting real-time clinical trial tracking in two cancer studies to speed up safety and efficacy monitoring. The move comes as CRISPR Therapeutics attracts investor attention ...
Non-model crop species represent a vast and diverse component of global agriculture, forestry, and horticulture, yet they are routinely underrepresented in ...
Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the ...
Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...
With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...
Intellia also separately announced positive topline data today from the Phase 3 HAELO clinical trial of lonvo-z in HAE. The trial met its primary and all key secondary endpoints, demonstrating that a ...
Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...
The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current ...
CRISPR Therapeutics plans to post clinical trial updates for multiple candidates this year. The company's stock could jump if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results